Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Targeting Sumoylation Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment

Li Du, Jiamin Guo, Zhenhua Chen, Jianjun Chen, Guido Marcucci, Steven T. Rosen

Blood (2023) 142 (Supplement 1): 411.

https://doi.org/10.1182/blood-2023-178037

Published: 2023

Journal Articles

Glycerolipid Metabolism Via the MGA-MYC-NME1-PGP Axis As a Key Regulator of Oxidative Phosphorylation in Richter's Transformation

Prajish Iyer, Brian Jiang, Girish Venkataraman, Joo Y Song, Tanya Siddiqi, Steven T. Rosen, Alexey Danilov, Lili Wang

Blood (2023) 142 (Supplement 1): 79.

https://doi.org/10.1182/blood-2023-179427

Published: 2023

Journal Articles

The Role of Macrophage Migration Inhibitory Factor (MIF) in Regulation of T-Cell Activity in Multiple Myeloma

Metin Gunes, Steven T. Rosen, Emine Gulsen Gunes

Blood (2023) 142 (Supplement 1): 4669.

https://doi.org/10.1182/blood-2023-180085

Published: 2023

Journal Articles

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)

John H. Baird, Marissa Morales Del Real, Joo Y. Song, Geoffrey P. Shouse, Alexey Danilov, Alex F. Herrera, Leslie L. Popplewell, Steven T. Rosen, Jennifer Davis, Baishakhi Barva, Lu Chen, Larry W. Kwak, Stephen J. Forman, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 4840.

https://doi.org/10.1182/blood-2023-182456

Published: 2023

Journal Articles

CD84 (SLAMF5) As a Potential Target for Immunomodulation in Cutaneous T-Cell Lymphoma (CTCL)

Metin Gunes, Steven T. Rosen, Emine Gulsen Gunes

Blood (2023) 142 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2023-184362

Published: 2023

Journal Articles

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine M. Zain

Blood (2023) 142 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2023-188053

Published: 2023

Journal Articles

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G. Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam

Blood (2022) 140 (25): 2697–2708.

https://doi.org/10.1182/blood.2022016624

Published: 2022

Includes: Supplemental data

Journal Articles

A Novel Approach to Achieve Long-Lasting Antitumor Immunity in Multiple Myeloma

Metin Gunes, Jessica Dang, Yate-Ching Yuan, Idit Shachar, Murali Janakiram, Mingye Feng, Steven T. Rosen, Emine Gulsen Gunes

Blood (2022) 140 (Supplement 1): 7092–7093.

https://doi.org/10.1182/blood-2022-167036

Published: 2022

Journal Articles

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Matthew Mei, Joycelynne Palmer, Ni-Chun Tsai, Hun Ju Lee, Iris Isufi, Leslie L. Popplewell, Lynne Smith, Lacolle Peters, Lara Rodriguez, James Godfrey, John H. Baird, Joo Y. Song, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Alex F. Herrera

Blood (2022) 140 (Supplement 1): 774–776.

https://doi.org/10.1182/blood-2022-167626

Published: 2022

Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1065–1067.

https://doi.org/10.1182/blood-2022-165699

Published: 2022

Journal Articles

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma

Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Steve Serrao, Pejman Solaimani, Lihua Elizabeth Budde, Matthew G. Mei, Leslie L. Popplewell, Tanya Siddiqi, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam

Blood (2022) 140 (19): 2024–2036.

https://doi.org/10.1182/blood.2022016747

Published: 2022

Includes: Supplemental data

Journal Articles

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesus San-Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana Advani, Stephen Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando Lopez-Guillermo, Maria Victoria Mateos, Elizabeth Macintyre, Ari M. Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano A. Pileri, Miguel Piris, Barbara Pro, Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier-Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz

Blood (2022) 140 (11): 1229–1253.

https://doi.org/10.1182/blood.2022015851

Published: 2022

Includes: Supplemental data

Journal Articles

Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression

Xu Cao, Yingyu Wang, Wencan Zhang, Xiancai Zhong, E. Gulsen Gunes, Jessica Dang, Jinhui Wang, Alan L. Epstein, Christiane Querfeld, Zuoming Sun, Steven T. Rosen, Mingye Feng

Blood (2022) 139 (22): 3290–3302.

https://doi.org/10.1182/blood.2021013901

Published: 2022

Includes: Supplemental data

Journal Articles

METTL3 Dysregulates RNA Splicing by Translational Control of Splicing Factors via m 6 A Modification in CLL

Yiming Wu, Meiling Jin, Mike Fernandez, Kevyn Hart, Aijun Liao, Stacey M. Fernandes, Tinisha McDonald, Lucy Ghoda, Daniel Roeth, Markus Kalkum, Raju Pillai, Jianjun Chen, Jennifer R Brown, Alexey V. Danilov, Steven T. Rosen, Tanya Siddiqi, Lili Wang

Blood (2021) 138 (Supplement 1): 499.

https://doi.org/10.1182/blood-2021-149691

Published: 2021

Journal Articles

Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma

Alex F. Herrera, Tamer Othman, Paul Frankel, Pamela Allen, Leslie L. Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V. Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T. Rosen, Elad Sharon, Joseph M Tuscano

Blood (2021) 138 (Supplement 1): 1407.

https://doi.org/10.1182/blood-2021-151188

Published: 2021

Journal Articles

Richter's Transformation after CD-19 Directed CAR-T Cells for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Amanda Blackmon, Alexey V. Danilov, Lili Wang, Raju Pillai, Hormoz Babaei Mirshkarlo, Steven T. Rosen, Tanya Siddiqi

Blood (2021) 138 (Supplement 1): 1430.

https://doi.org/10.1182/blood-2021-149815

Published: 2021

Journal Articles

Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study

Tanya Siddiqi, Pamela Clay, Kate Murray, Navshina Shekh, Alexandra Muir, Steven T. Rosen, Steven Coutre

Blood (2021) 138 (Supplement 1): 3754.

https://doi.org/10.1182/blood-2021-154203

Published: 2021

Journal Articles

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders

Farah R Abdulla, Weiwei Zhang, Xiwei Wu, Kord Honda, Hanjun Qin, Hyejin Cho, Christiane Querfeld, Jasmine Zain, Steven T. Rosen, Wing C. Chan, Vishwas Parekh, Joo Y. Song

Blood (2021) 138 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2021-152051

Published: 2021

Journal Articles

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Alex F. Herrera, Jasmine Zain, Kerry J. Savage, Tatyana A. Feldman, Jonathan E Brammer, Lu Chen, Leslie L. Popplewell, Lihua E Budde, Matthew Mei, Lori A. Leslie, Ranjit Nair, Chitra Hosing, Lacolle Peters, Stephen J Forman, Steven T. Rosen, Larry W. Kwak, Swaminathan P Iyer

Blood (2021) 138 (Supplement 1): 133.

https://doi.org/10.1182/blood-2021-151105

Published: 2021

Journal Articles

MGA deletion Leads to Richter's Transformation Via NME1

Prajish Iyer, Bo Zhang, Tingting Liu, Meiling Jin, Kevyn Hart, Joo Y. Song, John Chan, Raju Pillai, Tanya Siddiqi, Alexey V. Danilov, Steven T. Rosen, Lili Wang

Blood (2021) 138 (Supplement 1): 252.

https://doi.org/10.1182/blood-2021-148953

Published: 2021

NARROW

Targeting Sumoylation Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment

Glycerolipid Metabolism Via the MGA-MYC-NME1-PGP Axis As a Key Regulator of Oxidative Phosphorylation in Richter's Transformation

The Role of Macrophage Migration Inhibitory Factor (MIF) in Regulation of T-Cell Activity in Multiple Myeloma

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)

CD84 (SLAMF5) As a Potential Target for Immunomodulation in Cutaneous T-Cell Lymphoma (CTCL)

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

A Novel Approach to Achieve Long-Lasting Antitumor Immunity in Multiple Myeloma

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression

METTL3 Dysregulates RNA Splicing by Translational Control of Splicing Factors via m 6 A Modification in CLL

Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma

Richter's Transformation after CD-19 Directed CAR-T Cells for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

MGA deletion Leads to Richter's Transformation Via NME1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only